Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Roche Holding AG Basel American Depositary Shares (OP:RHHBY)

58.69 +0.90 (+1.56%)
Streaming Delayed Price Updated: 2:18 PM EST, Feb 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Roche Holding AG Basel American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
27 28 Next >
News headline image
Generative AI Unleashes a New Era in Genome Editing, Outperforming Nature in Protein Design
London, UK – October 2, 2025 – In a monumental stride for biotechnology and medicine, generative artificial intelligence (AI) has achieved a scientific breakthrough, demonstrating an unprecedented... 
Via TokenRing AI
Topics Artificial Intelligence
News headline image
GSK Leaps Into Buy Zone On Surprise Departure Of CEO Emma Walmsley ↗
Shares had broke out earlier this month, but have floundered at the lower boundary of the chart pattern. 
Via Investor's Business Daily
News headline image
Trump's 100% Pharmaceutical Tariff: The $270 Billion Manufacturing War That Could Reshape Your Medicine Cabinet ↗
Trump’s sweeping 100% pharmaceutical tariff starting October 1 triggers massive $270 billion industry investment surge, creating clear stock market winners like Eli Lilly while foreign-de 
Via Benzinga
Topics Government World Trade
89bio Stock Skyrockets After Roche’s $3.5B Buyout Offer: Retail Bullish, But A Wall Street Analyst Is Cautious ↗
Via Stocktwits
Why Did 89bio Stock Nearly Double In Value Today? ↗
Via Stocktwits
News headline image
Prediction: 2 Stocks That Will Be Worth More Than BigBear.ai 5 Years From Now ↗
BigBear.ai is bigger than both of these AI-focused companies now. That could change. 
Via The Motley Fool
Topics Artificial Intelligence
Trump Shocks Pharma With 100% Tariff On Imported Drugs Unless Companies Build In America ↗
Via Stocktwits
Topics Government
News headline image
Eli Lilly Ends Bimagrumab Obesity Study Weeks After Launch ↗
On Wednesday, Eli Lilly & Co. (NYSE: LLY) ended a mid-stage study of its experimental drug bimagrumab in obesity patients with type 2 diabetes, just weeks after it began. 
Via Benzinga
News headline image
Viking Therapeutics Stock Gets Boost From Pfizer-Metsera Deal, Says BTIG — Retail Slams Rivals For Buying ‘Inferior Pipelines’ ↗
BTIG said Pfizer’s $7.3 billion Metsera acquisition sharpens its clinical updates and strategic optionality. 
Via Stocktwits
Big Pharma Eyes China: J&J And Roche Reportedly In Talks For Henlius’ Experimental Cancer Drug ↗
Via Stocktwits
Novartis Rides Bullish Retail Mood, Roche Faces Gloom Amid Swiss-US Trade Concerns ↗
Via Stocktwits
News headline image
Big Pharma's Epicenter Shift: Eli Lilly and the Reshaping of the Weight-Loss Drug Market
The pharmaceutical industry is currently witnessing a transformative battle for dominance in the burgeoning weight-loss drug market, with Eli Lilly (NYSE: LLY) firmly at the forefront. What was once a... 
Via MarketMinute
Topics Economy Intellectual Property
News headline image
Roche Targets Top Spot In Weight Loss Drug Market ↗
Roche advances weight loss drug CT-388 to Phase III, boosts pipeline with major acquisitions. 
Via Benzinga
News headline image
The Pharmaceutical Revolution: AI, Gene Therapies, and Obesity Drugs Reshape a Trillion-Dollar Market
The global pharmaceutical sector stands at the precipice of a monumental transformation, driven by an unprecedented convergence of scientific breakthroughs, technological innovation, and evolving... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
The Healthcare Horizon: Navigating Innovation, Policy Shifts, and Evolving Patient Care
The global healthcare industry is currently in the midst of a profound metamorphosis, characterized by a rapid influx of technological innovation, significant shifts in policy, and evolving patient... 
Via MarketMinute
Topics Artificial Intelligence
News headline image
Deal Dispatch: Need M&A Approval? FCC Chair Explains How To Get It ↗
The "Jimmy Kimmel Live" drama coincided with reports of tit-for-tat maneuvering between the FCC and corporations desperate for deal approval. 
Via Benzinga
News headline image
Roche To Acquire 89bio For $2.4 Billion In Liver And Cardiometabolic Push ↗
Roche is acquiring 89bio for $2.4 billion plus potential milestone payouts, bolstering its pipeline with late-stage MASH drug pegozafermin. 
Via Benzinga
News headline image
Roche Digs Into Obesity-Tied Diseases With $3.5 Billion 89bio Buyout ↗
The company is now focusing on MASH, a form of fatty liver disease common in people with obesity and type 2 diabetes. 
Via Investor's Business Daily
News headline image
1 Super Stock Down More Than 20% to Buy Hand Over Fist, According to Wall Street ↗
The positives for this big drugmaker appear to outweigh the negatives. 
Via The Motley Fool
Topics Earnings Government World Trade
News headline image
BioNTech Surges 10% On Promising Test Results For Its Cancer Smart Bomb ↗
The company's DualityBio-partnered drug met the pre-specified bar for success in a pivotal study. 
Via Investor's Business Daily
News headline image
BioNTech Advances On Positive Phase 3 Breast Cancer Drug Data ↗
BioNTech and DualityBio reported Phase 3 success for trastuzumab pamirtecan in HER2 breast cancer, setting stage for regulatory submission in China. 
Via Benzinga
News headline image
2 High-Yield Dividend ETFs You Can Buy With $200 in September and Hold Forever ↗
You don't need to be rich to begin building a passive income stream that could fuel your retirement dreams. 
Via The Motley Fool
Topics ETFs Retirement Stocks
News headline image
2 Brilliant Vanguard Index Funds to Buy With $1,000 in August and Hold Forever ↗
These Vanguard index funds offer diversified exposure to many of the most influential stocks in the world. 
Via The Motley Fool
Topics ETFs
News headline image
This Biotech Stock Could Soar on Upcoming Clinical Data ↗
This weight loss drugmaker may be significantly undervalued right now. 
Via The Motley Fool
News headline image
FDA Probes Death Of 8-Year-Old Who Received Sarepta's Elevidys ↗
FDA probes Elevidys after an 8-year-old's death in Brazil; Sarepta and Roche say the death was unrelated to gene therapy treatment. 
Via Benzinga
News headline image
Roche Bets Big On Alzheimer’s Prevention With New Trial As Duchenne Drug Setback Looms ↗
The pharma company is advancing a third late-stage study of its experimental Alzheimer’s drug trontinemab, which uses brain shuttle technology to bypass the blood-brain barrier and clear amyloid... 
Via Stocktwits
News headline image
The Median Retirement Savings for American Households Is $87,000. Here Are 3 Incredible Stocks to Buy Now and Hold for Decades. ↗
You should probably be saving more, but even if you can't do that, you can get more out of the money you are able to save. 
Via The Motley Fool
Topics Artificial Intelligence Retirement
News headline image
Sarepta Gets Thumbs Down From Regulators Regarding Elevidys Gene Therapy ↗
Sarepta and Roche face a regulatory setback as the EMA's CHMP issues a negative opinion on Elevidys for Duchenne muscular dystrophy patients. 
Via Benzinga
News headline image
Sarepta Stock Slumps After EU Regulator Recommends Refusing Approval To Its Contentious Gene Therapy: Retail Expects Stock Bounceback ↗
Roche announced on Friday that it plans to continue working with the EMA to explore a potential path forward. 
Via Stocktwits
Topics Death
News headline image
Abivax Hits The Stratosphere, Up 500%, On 'Potentially Disruptive' Results ↗
The results represent a best-case scenario for the company in treating inflammatory bowel disease, according to one analyst. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 9
...
27 28 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.